Related references
Note: Only part of the references are listed.Severe hyponatraemia in two patients with breast cancer caused by low-dose cyclophosphamide and precipitated by aprepitant
Shefali Parikh et al.
BMJ CASE REPORTS (2022)
Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China
Shangzhu Zhang et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2021)
Neuropsychiatric involvement in systemic lupus erythematosus: A review
Irene Carrion-Barbera et al.
AUTOIMMUNITY REVIEWS (2021)
Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review
D. A. Papachristos et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)
Oral cyclophosphamide-induced posterior reversible encephalopathy syndrome in a patient with ANCA-associated vasculitis: A case report
Yire Kim et al.
WORLD JOURNAL OF CLINICAL CASES (2021)
Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus
Meggan Mackay et al.
CURRENT OPINION IN NEUROLOGY (2020)
Review: Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions
John G. Hanly et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus: current state of the art and novel approaches
M. Postal et al.
LUPUS (2017)
Advanced MRI techniques: biomarkers in neuropsychiatric lupus
N. Sarbu et al.
LUPUS (2017)
The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy
Martina Ahlmann et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Spinal astrocytic activation contributes to mechanical allodynia in a rat model of cyclophosphamide-induced cystitis
Bolong Liu et al.
MOLECULAR PAIN (2016)
Neuropsychiatric lupus: a mosaic of clinical presentations
Shaye Kivity et al.
BMC MEDICINE (2015)
Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database
Trevor Hill et al.
BMC PSYCHIATRY (2015)
A case of PRES in an active lupus nephritis patient after treatment of corticosteroid and cyclophosphamide
M. Jabrane et al.
RHEUMATOLOGY INTERNATIONAL (2015)
Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers
Helene Jeltsch-David et al.
NATURE REVIEWS NEUROLOGY (2014)
Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases
Diana Dan et al.
SWISS MEDICAL WEEKLY (2014)
Cyclophosphamide-Induced Severe Acute Hyponatremic Encephalopathy in Patients with Breast Cancer: Report of Two Cases
Michelle Baker et al.
CASE REPORTS IN ONCOLOGY (2014)
Epilepsy Associated with Systemic Autoimmune Disorders
Orrin Devinsky et al.
EPILEPSY CURRENTS (2013)
Neuropsychiatric Syndromes in Systemic Lupus Erythematosus: A Meta-Analysis
Avraham Unterman et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2011)
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus
J. G. Hanly et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Cyclophosphamide and cancer: golden anniversary
Ashkan Emadi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus
L Barile-Fabris et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study)
L Stojanovich et al.
LUPUS (2003)